Inflammatory bowel disease (IBD), which mainly comprises two conditions known as ulcerative colitis and Crohn’s disease, is characterized by chronic inflammation of the intestinal tract and affects millions. IBD is caused by factors ranging from genetic mutations to micro and macro environments outside and inside the gut.

This webinar introduces participants to commonly used in vivo gastrointestinal models with emphasis on chemically induced IBD models. The acute versus chronic nature of the disease and how the models reflect these conditions are discussed. Relevant endpoints used in IBD drug discovery study design are also addressed.


  • Harun Rashid, BPharm, MPharm, PhD, Principal Scientist, Charles River
  • Agathe Bédard, DVM, DES, DACVP, Veterinary Pathologist II, Charles River